Conflict of interest
H. Mukai received research grant from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K. K., Pfizer Inc. and Sanofi K. K.; S. Noguchi serves as an advisor of Taiho Pharmaceutical Co., Ltd., and received honoraria from Astra Zeneca Co., Ltd., and received research grant from Astra Zeneca Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K. K. and Takeda Pharmaceutical Co., Ltd.; H. Iwase received honoraria from Astra Zeneca Co., Ltd., and received research grant from Astra Zeneca Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd.; J. Kurebayashi received honoraria from Takeda Pharmaceutical Co., Ltd.; M. Toi received research grant from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd. and Novartis Pharma K. K.; Y. Tokuda received research grant from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K. K.; Other authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is an English digested edition of the Nyugan Shinryo guideline 2013 nen ban, published by Kanehara & Co., LTD.
About this article
Cite this article
Mukai, H., Noguchi, S., Akiyama, F. et al. 2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission. Breast Cancer 22, 1–4 (2015). https://doi.org/10.1007/s12282-014-0550-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-014-0550-2